153 - Molnupiravir Exhibits a High Barrier to the Development of SARS-CoV-2 Resistance in vitro

Thursday, October 20, 2022

12:15 PM – 1:30 PM US ET

Location: Hall B + C

Presenting Author(s)

Julie Strizki, PhD

Principal Scientist
Merck & Co., Inc.
West Point, Pennsylvania, United States

NM

Nicholas Murgolo, PhD

Merck & Co., Inc.
Kenilworth, New Jersey, United States
JG

John Gaspar, PhD

Merck and Co.
Boston, Massachusetts, United States
JH

John Howe, PhD

Merck and Co.
GREEN BROOK TOWNSHIP, New Jersey, United States
BH

Beth Hutchins, PhD

Director
Merck and Co,
Rahway, New Jersey, United States
HM

Hiroshi Mohri, PhD/MD

Senior scientist
Aaron Diamond Research Institute, Columbia University
New York, New York, United States
David D. Ho, MD

Director, Aaron Diamond AIDS Research Center, Professor of Medicine
Columbia University Vagelos College of Physicians and Surgeons
New York, NY, United States
DH

Daria Hazuda, PhD

Merck & Co., Inc.
Kenilworth, New Jersey, United States
Jay Grobler, PhD

Executive Director - Infectious Disease and Vaccines
Merck & Co., Inc.
Kenilworth, New Jersey, United States